Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AVTO FINRA deleted symbol:
https://otce.finra.org/otce/dailyList?viewType=Deletions
AVTO SEC Suspension because of questions regarding the adequacy and accuracy of information about the company.
https://www.sec.gov/litigation/suspensions/2019/34-85835.pdf
Order:
https://www.sec.gov/litigation/suspensions/2019/34-85835-o.pdf
AVTO .0055 looking good here: http://investorshub.advfn.com/boards/msgsearch.aspx?searchstr=avto
and yes data suggests: http://www.profitspi.com/stock/view.aspx?v=price-and-chart&p=2259&i=AVTO&pv=recent-symbols&pp=AVTO#&&vs=635146517975272108
AVTO 0055 NITE just finally moved off and 0075 is up 220k vol. today, maybe news soon
AVTO is on the REH Sho List
Good day to hammer $AVTO
Its on the REG SHO sec threshold list
http://www.phlx.com/trader.aspx?id=RegSHOThreshold
lol..only on the pinks can a stock with no operations, no current T/A, no news and no prospects, a jailed former CEO and no current info rise 300% in a day on a pre-loaded pump.
Congrats to those of us who got out before it crashes and thanks to ALL of you for the weekend spending money woohoo!
I added it to watchlist... AVTO looks interesting
Thanks, personally don't think this was 'the-run', volume alarms went off for day traders, etc.
Let's see what happens next today, next week.. or ?
sc
AVTO .0099 to many shares left on the table from an outside iHub buyer.... this run was quick but I don't think it has anything to do with the loading process. Could be wrong...
Looking for another move above .01 again
yup/some group loaded
689% lol nice one GL SC
AVTO 23.6 million that day and very little change... MM/Group Strategy Pre_Event Loading.
AVTO pre-load big time, fresh play.... look out! http://investorshub.advfn.com/boards/msgsearch.aspx?searchstr=avto
http://www.profitspi.com/stock/view.aspx?v=price-and-chart&p=2259&i=AVTO&pv=recent-symbols&pp=AVTO
How dare someone pre-load, lol
AVTO .015 amazing/weeeeeeeeeeeeeeeee
Nice find gl here AVTO
Can anyone fill me in
AVTO
On radar AVTO
AVTO .01 on your .0015er weeeeeeeeeeeeee
AVTO on 7/09 someone knew of future event? :) http://www.profitspi.com/stock/view.aspx?v=price-and-chart&p=2259&i=AVTO&pv=recent-symbols&pp=AVTO
AVTO .008 up/wow
AVTO .006 strong move here
AVTO .009 1 - 20k buy on-watch http://www.profitspi.com/stock/view.aspx?v=price-and-chart&p=2259&i=AVTO&pv=recent-symbols&pp=AVTO#&&vs=634958682563721255
the volume jumped compared to the past, 74k is a mmonths worth.
looked good the first day. had to pay .30 to buy it. bought 500shrs. theres no float.
Bought some AVTO today, just to see if it goes anywhere.
i might try it for a little bit. might take a while ,but could pay.
1.7m now 23m+roy later. come off the e.
i hope they will file. lol
LOS ANGELES, CA--(MARKET WIRE)--Apr 26, 2007 -- Avantogen Oncology, Inc. (OTC BB:AVTOE.OB - News) today announced that it has signed an agreement with SciClone Pharmaceuticals, Inc. (NasdaqGM:SCLN - News) with respect to its lead drug candidate, RP101, for the treatment of pancreatic cancer.
Under the terms of the agreement, Avantogen Oncology and its wholly owned subsidiary, Resistys, Inc., assigned all of their rights to RP101 to SciClone in exchange for approximately $1.7 million in upfront fees, success-based regulatory and commercial payments of up to $23.3 million and royalties on future sales. The milestone and royalty payments will be shared with RESprotect GmbH, the owner of the intellectual property rights to RP101. SciClone will develop and commercialize RP101, initially in combination with gemcitabine, for the treatment of pancreatic cancer in the U.S. and Canada.
"We are delighted to sign this agreement with SciClone Pharmaceuticals. This will ensure the continued development of RP101, a program which we believe holds significant promise to produce a meaningful therapeutic for patients with advanced pancreatic cancer," said Chris Nowers, Chief Executive Officer of Avantogen Oncology, Inc.
Friedhelm Blobel, Ph.D., President and Chief Executive Officer of SciClone Pharmaceuticals, Inc., added, "We are excited to complete this agreement with Avantogen Oncology, Inc. We believe that RP101 has the potential to offer a new therapeutic regimen to pancreatic cancer patients, and we are committed to moving this program forward expeditiously."
"We are pleased with the level of cooperation that we have received from RESprotect and SciClone Pharmaceuticals in achieving what we believe is an agreement that provides meaningful incremental value for our shareholders," stated Dr. William Ardrey, Chairman of Avantogen Oncology, Inc.
About RP101
Standard chemotherapy typically offers patients with advanced pancreatic cancer a median survival of approximately 6 months. In contrast, two open label, multi-center, Phase 1 trials indicated that RP101 in combination with standard chemotherapy was associated with a median survival of approximately 14 months and 9 months, when compared to well matched historical control patients receiving standard chemotherapy alone.
Forward-Looking Statements
Statements contained in this press release that are not historical information are forward-looking within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that may cause the company's actual results to differ materially from stated expectations. Such potential risks and uncertainties include, among others, the results of clinical trials, access to capital, the effectiveness and pace of current and future product development efforts, regulatory approvals, product demand and market acceptance, the impact of competitive products and other factors which may be identified from time to time in the company's SEC filings and other public announcements.
About Avantogen Oncology, Inc.
Avantogen Oncology is an international biotechnology company focused on developing potential product candidates in oncology.
Avantogen Oncology, Inc. is traded on the OTC Bulletin Board under the symbol AVTOE.OB.
For further information, visit www.avantogenoncology.com.
Contact:
Contact:
Chris Nowers,
Chief Executive Officer,
Avantogen Oncology, Inc.
2121 Avenue of the Stars,
Suite 2550,
Los Angeles,
CA 90067, USA
Tel: +1 310 277 2077
Email: Email Contact
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
35
|
Created
|
04/26/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |